Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management

by | PRNewswire Asia

Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of...

APR Corporation Announces 2025 Q3 Earnings and Hosts Online Earnings Presentation Call

by | PRNewswire Asia

SEOUL, South Korea, Nov. 3, 2025 /PRNewswire/ — The major player of K-Beauty phenomenon, APR Corporation (APR Corp, CEO Byunghoon Kim) has announced that it will release its provisional third-quarter results for 2025 and hold an online earnings presentation...

Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS

by | PRNewswire Asia

Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes. YOKOHAMA, Japan, Nov. 3, 2025 /PRNewswire/ — Johnson & Johnson MedTech, a global leader in cardiac...

Biomom Reinvents "Snow" with Five-Layer Safety Packaging — Stronger Protection and Greater Convenience for Kids' Probiotics

by | PRNewswire Asia

SEOUL, South Korea, Nov. 3, 2025 /PRNewswire/ — Health supplement brand Biomom has introduced upgraded, hygienic packaging for its flagship probiotic "Biomom Snow." The renewal features five-layer safety stick and pillow packaging designed to...

GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'

by | PRNewswire Asia

YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ — GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine ‘BARYTHRAX inj. (GC1109)’ have been published...

Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

by | PRNewswire Asia

HONG KONG, Nov. 3, 2025 /PRNewswire/ — Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for first-line treatment of triple-negative breast cancer (TNBC) has been...